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Retinoic acid is an active metabolite of retinol (ROL, vitamin A)
that plays an important role in growth and differentiation of a
variety of cell types (Gudas et al, 1994). Retinoids also inhibit the
growth of cancer cells (Lotan, 1980) and are useful in the treat-
ment and prevention of human cancer (Bollag and Holdener,
1992). In head and neck squamous cell carcinoma (HNSCC) 13-
cis-retinoic acid (13cRA) was successful in the prevention of
second primary tumours (Hong et al, 1990). Retinoids demonstrate
the ability to induce objective responses in oral leukoplakia (Hong
and Itri, 1994). This is a whitish and reddish plaque in the epithe-
lial lining in the oral cavity that have a relatively high risk to
become malignant. For 13cRA a response rate (based on both
partial and complete responses) varying between 55% and 87%
has been reported (Lippman et al, 1988; Hong and Itri, 1994). All-
trans-retinoic acid (ATRA) was shown to be active in 59% of
leukoplakia patients (Koch, 1978). The activity of retinoids,
however, is associated with serious side effects and intrinsic and
acquired resistance does occur (Hong and Itri, 1994). Acquired
resistance to ATRA in leukemia was found to be a consequence of
enhanced catabolism of ATRA (Muindi et al, 1994). In contrast, an
inverse relationship was found between intrinsic ATRA resistance
and ATRA catabolism in HNSCC (Braakhuis et al, 1997; Klaassen
et al, 2001a). This paradoxical finding suggests that the molecular
mechanisms underlying RA-resistance in HNSCC are different.
The possible mechanisms explaining (the lack of) the effect of
retinoids have not been elucidated but are thought to be mediated
through retinoid binding to specific nuclear retinoid receptors,
with modulation of the expression of genes involved in growth and
differentiation (Oridate et al, 1996). Recent data show that in
HNSCC especially the expression of RAR-γ is important for
retinoid induced growth inhibition (Le et al, 2000; Klaassen et al,
2001b). 
ATRA is a naturally occurring compound that shows a much
more avid binding to retinoic acid receptors than 13cRA (Åström
et al, 1990). Whereas ATRA preferentially binds retinoic acid
receptors (RARs), its stereoisomer 9-cis-RA (9cRA) has a high
binding affinity for RARs as well as retinoid X receptors (RXRs)
(Heyman et al, 1992). Details on their binding and transactivating
activity has been reported earlier in full detail (Allenby et al, 1993;
Sun et al, 1997). Related to differences in receptor binding affini-
ties between the three stereoisomers, different effects on growth
and metabolism may be expected. 
Differences in metabolic rates and/or type of metabolites
formed between the various retinoid compounds may determine
the growth inhibiting capacities of these compounds. One impor-
tant route of ATRA metabolism consists of hydroxylation at posi-
tion 4 of the cyclohexenyl ring to form 4-hydroxy-RA, which is
readily oxidized to 4-oxo-RA. Other metabolic pathways of ATRA
include isomerization, decarboxylation and glucuronidation
processes (Rockley et al, 1980; Roberts et al, 1980; Sass et al,
1994). In vitro, 4-hydroxylation of ATRA is mediated by a
cytochrome P450 (CYP)-dependent mono-oxogenase system that
requires NAPDH and oxygen (Roberts et al, 1980). 
The present study was undertaken to investigate to what extent a
panel of retinoids, including 13cRA, is able to inhibit growth of
HNSCC cells and cultures of normal oral keratinocytes (OKC).
Growth inhibition was related to retinoid turnover and the pattern
of metabolites formed. 
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Chemicals 
13cRA and retinol (ROL) were obtained from Sigma (St. Louis,
MO), ATRA from Acros Chimica (Geel, Belgium); 4-oxo-all-
trans-RA (4-oxo-RA) and 4-oxo-13cRA were gifts from Dr U.H.
Wiegand (Hoffmann-la Roche, Basel, Switzerland); 4-hydroxy-
RA (4-OH-RA) and 18-hydroxy-RA (18-OH-RA) were gifts
from Dr L. Foley (Roche Pharmaceuticals, Nutley, NJ). All
compounds were dissolved in dimethyl sulfoxide (DMSO) and
stored as 10–3 mol l–1 stock at –80˚C under nitrogen. For each
experiment, working dilutions were freshly prepared in the
appropriate cell culture medium. Final DMSO concentration was
always lower than 0.1% and did not affect cell growth. All
handling with retinoids was performed in subdued light and in
the presence of 0.1% BSA to prevent absorption to plastics
(Klaassen et al, 1999). 
Cells and culture conditions 
Primary OKC were obtained from the uvulas of non-cancer
patients who underwent uvulopalatopharyngoplasty. The mucosal
layer was stripped from the tissue and cells were isolated and
cultured as described previously (Reid et al, 1997) in 6-well
culture plates in keratinocyte growth medium (KGM) (Life
Technologies, Paisley, UK) supplemented with growth factors
(BPE and rEGF), gentamycin sulphate (final concentration 5 µ g
ml-1) and amphotericin B (final concentration 0.5 µ g ml–1) (all
from Life Technologies). At 70% confluency, primary cultures of
keratinocytes were subcultured and plated at a density of 105
cells/well. Keratinocytes were used for experiments at passage 3,
when they reached 70–80% confluence. Human HNSCC cell lines
UM-SCC-35,  –22A and –14C were provided by Dr TE Carey
(University of Michigan, Ann Arbor, MI) and are described else-
where (Carey, 1990). An RA-resistant subline, UM-SCC-35R, was
established from the RA-sensitive UM-SCC-35 cell line by
exposing it to increasing concentrations of ATRA (10–8to 10–6mol l–1)
during a period of 8 months. HNSCC cells were maintained
in Dulbecco’s Modified Essential Medium (DMEM, Life
Technologies) supplemented with 5% FCS (ICN Biomedicals,
Irvine, UK) and 50 units ml–1 penicillin, 50 µ g ml–1 streptomycin
(Life Technologies). 
Growth inhibition assays 
The dose response effect on cell proliferation was determined
with the ‘SRB-assay’. Details of the assay have been described
previously (Braakhuis et al, 1993). In short, cells (1000–4000 per
well) were plated in 96-well plates in DMEM/5% FCS or
KGM/0.1% BSA for HNSCC cell lines and oral keratinocyte
cultures, respectively, and were allowed to grow for 72 h (the
‘lag phase’). After this phase the medium was replaced by
medium containing the appropriate retinoid with a final concen-
tration ranging from 10–9 to 10–6 mol l–1. Growth was assayed
after another 72 h incubation (the ‘log phase’), by staining the
cellular protein with sulphorhodamine B (SRB; Sigma) and spec-
trophotometric measurement of the absorption at 540 nm with a
microplate reader (Labsystems Multiskan, Helsinki, Finland).
Growth of untreated cells during the log phase must at least have
doubled its initial value. 
Metabolism experiments 
Keratinocytes and HNSCC cells were plated at a density of 105
cells per well in 6-well plates. Upon 70–80% confluence, the
medium was removed and replaced by medium containing 1 µ M
RA, being KGM with 0.1% BSA for keratinocytes (Klaassen et al,
1999) or DMEM with 5% FCS for HNSCC cells. As a control
retinoid containing medium without cells was included during the
incubation period. From the medium two samples of 350 µ l were
taken and after removal of the residual medium the cells were
washed once with phosphate-buffered saline and collected in 350
µ l trypsin/EDTA. The samples were stored at –80˚C under
nitrogen until retinoid extraction. 
Determination of the turnover rate 
Retinoids were analysed by reverse-phase HPLC after extraction
with acetonitrile, as described previously (Teerlink et al, 1997;
Klaassen et al, 2001a). The amount of retinoid compound at each
time point was calculated relative to the amount of the medium
control at the start of the experiment. The turnover rate was taken
as the difference between 4 and 24 h, corrected for the decrease in
the medium controls during this period. Next, this relative amount
was converted to absolute amounts in pmol by use of the external
standards. The turnover rate was expressed in pmol per mg protein
per hour. Protein content of cell extracts was determined on the
pellet with the Bio-Rad protein assay (Bio-Rad, Hercules, CA) 
RESULTS 
Growth inhibition of various retinoid compounds in
HNSCC cell lines 
The relative growth of four HNSCC cell lines treated with ATRA, its
isomers (13cRA and 9cRA), and its precursor ROL is illustrated in
Figure 1. Two cell lines (UM-SCC-22A and UM-SCC-35) exerted a
dose-dependent growth inhibition for all compounds, while the other
two cell lines (UM-SCC-14C and UM-SCC-35R) were insensitive;
UMSCC-35 was the most sensitive cell line. 4-oxo-metabolites of
ATRA and 13cRA were tested in four cell lines to find out whether
these catabolites were able to induce growth inhibition and whether a
lack of 4-hydroxylation could explain the lack of response in the
insensitive cell lines. From Figure 1 it can be seen that the level of
growth inhibition by 4-oxo-RA and 4-oxo-13cRA was similar to that
of the other retinoid compounds. In addition, OKC cultures from
different individuals were exposed to four retinoids as well; a
moderate dose-dependent growth inhibition was observed that was
not different between the various compounds (Figure 1). 
Metabolism of ATRA, 13cRA, 9cRA and ROL in HNSCC
cells and OKC cultures 
A summary of the turnover rate of all different compounds and the
metabolites formed in the medium and pellets is given in Table 1
and Figure 2. The rate of retinoid turnover was more cell line than
compound dependent. In general, UM-SCC-35 showed the highest
turnover rate for all compounds, UM-SCC-35R and UM-SCC-14C
the lowest and UM-SCC-22A an intermediate turnover rate;
turnover rates in OKC were comparable to the turnover rates in
UM-SCC-35R and UM-SCC-14C. The turnover rate of ROL was
the highest of all compounds in all cell lines. 
Retinoids in head and neck cancer 631
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In general, the metabolites formed were different between
HNSCC cell lines and OKC (Table 1). Polar metabolites in ‘group
b’ and metabolites in ‘group a’ (Figure 2) were only found in
HNSCC cell lines, but not in OKC. The widest variety of metabo-
lites was found in the medium of cell line UM-SCC-35, probably
due to its high turnover rate. 5, 6-epoxy-RA was, for instance, only
found in medium of UM-SCC-35. After 13cRA and 9cRA exposure,
a relative high formation of polar metabolites in UM-SCC-35 and
UM-SCC-35R was observed, similar as was reported for ATRA
(Klaassen et al, 2001a). Metabolism of ROL resulted in the forma-
tion of an unknown product, with a retention time a little longer
than that of ATRA (Figure 2, ‘d’), which was found in almost
every medium and cell fraction of cancer cell lines as well as OKC,
whereas a group of unknown peaks named ‘c1’ was only found in
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Figure 1 Relative growth of cells exposed to various concentrations of ATRA, 13cRA, 9cRA, ROL, 4-oxo-13cRA and 4-oxo-RA as compared to untreated cells.
OKC cultures (from four different individuals) were exposed to the first four drugs. Growth was assessed with the ‘SRB-assay’ and experiments were performed
at least three times. Average values are shown and coefficients of variation were less than 5% (HNSCC lines) and 13% (OKC cultures), respectively
Table 1 Retinoid metabolism in four HNSCC cells and OKC exposed to 1 mM of four different retinoids 
HNSCC line Retinoid
Metabolism* Metabolites** 
Mean SD Pellet Medium 
14C ATRA 13.3 9.2 e a,b 
13cRA 78.7 27.2 d2 a,b 
9cRA 59.3 13.2 e a,b 
ROL 223.7 84.5 d1 d1 
22A ATRA 104.8 67.9 e a,b 
13cRA 154.1 76.3 d2 a,b 
9cRA 139.3 45.9 e a,b 
ROL 349.9 12.7 d1 d1 
35 ATRA 1,016.0 413.2 e a,b 
13cRA 949.5 53.0 e a,b 
9cRA 962.3 88.2 b a,b,c 
ROL 1,336.8 76.7 c1 a,b,c1,d1 
35R ATRA 52.7 25.4 b a,b 
13cRA 6.9 9.8 b,d2 a,b 
9cRA 23.4 5.5 b a,b 
ROL 111.7 2.9 c1,d1 c1,d1 
OKC ATRA 14.8 19.0 e e 
13cRA 38.8 20.5 d2 e 
9cRA 12.0 12.5 e e 
ROL 98.7 78.5 d1 d1 
The profiles of 72 h exposure are shown. Note that the names of the cell lines have been abbreviated; the prefix
‘UM-SCC-’ has been omitted. Experiments were performed in triplicate, OKC cultures were from four different
individuals. *Metabolism determined from HPLC analysis expressed as relative decrease in medium and cells
together of the corresponding retinoid between 4 and 24 h exposure as compared to medium controls at t = 0 h
per mg protein per hour. **Metabolites in medium and in cell pellets determined from HPLC analysis. 
Metabolites: a, between 5 and 10 min (retention time); b, between 10 and 15 min; c, between 15 min and 13cRA;
d, between ATRA and ROL; e, no metabolites. A more detailed explanation of the metabolites mentioned is given
in Figure 2. Retinoids in head and neck cancer 633
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UM-SCC-35 and UM-SCC-35R (Table 1). Another group of
unknown peaks named ‘d2’, corresponding with retention times
between that of ATRA and ROL, was found after exposure to
13cRA in all cellular fractions, except in that of UM-SCC-35. The
unidentified peaks described above were not found in medium
without cells or in untreated cells. 
As an example, profiles of metabolites formed in the medium of
UM-SCC-35 after exposure to four retinoids are shown in Figure 3.
Each compound corresponds with an unique pattern of metabo-
lites. In the other HNSCC cell lines generally similar peak profiles
as in UM-SCC-35 were found. Following ROL and 9cRA expo-
sure some more peaks were detected in UM-SCC-35 and –35R
(Table 1). Co-elution of peaks with authentic retinoids of absorp-
tion at the two wavelengths of detection with the corresponding
ratios of the reference compounds enabled the identification of 4-
oxo-RA (1), 4-oxo-13cRA (2), 4-OH-RA (3), 18-OH-RA (4), and
an unknown peak (A) after exposure to ATRA (Figure 3). The
major metabolite of ATRA in UM-SCC-35 was 4-OH-RA. 13cRA
was metabolized to products identified as 4-oxo-13cRA (2) and
three unknown peaks (A, B and C), of which peak A and B were
the highest (Figure 3). Metabolism of 9cRA resulted in peaks
corresponding with the same metabolites as found with 13cRA
metabolism, but with higher amounts of peak A and a substantially
lower amount of peak B and an additional peak co-eluting with 5,
6-epoxy-RA (peak 5). The level of the polar metabolites (Figure 2,
‘group  b’) formed after 13cRA or 9cRA exposure was much
higher than that of the group of polar metabolites formed from
ATRA. 
After ATRA exposure, as compared to other HNSCC cell lines a
relatively high isomerization (up to 10%) was found to 13cRA in
UM-SCC-22A, UM-SCC-14C and OKC and a relatively high
level of polar metabolites in UM-SCC-35R. In UM-SCC-22A, UM-
SCC-14C and OKC a relatively high isomerization to ATRA after
13cRA exposure (up to 10%) and a relatively high isomerization to
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Figure 2 Compilation of all metabolites formed in cells and medium after
addition of ATRA, 9cRA, 13cRA or ROL is shown. This chromatogram is
necessary for the interpretation of Table 1 and shows 4-oxo-RA (peak 1), 
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in groups of peaks as follows: a, polar metabolites corresponding to peaks with
retention times between 5 and 10 min; b, polar metabolites corresponding to
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13cRA; d, peaks with retention times between that of ATRA and ROL; c1,
peaks found after exposure to ROL in medium and cells of UM-SCC-35 and
UM-SCC-35R; d1, peak found after exposure to ROL in medium and cells of
HNSCC cell lines and OKC; d2, peaks found in cells of HNSCC cell lines and
OKC after exposure to 13cRA. Peak 5 (5,6-epoxy-RA) was found only in
medium of UM-SCC-35 after exposure to 9cRA 
− 10
10.0
8.0
6.0
4.0
2.0
0.0
10.0
8.0
6.0
4.0
2.0
0.0
10.0
8.0
6.0
4.0
2.0
0.0
10.0
8.0
6.0
4.0
2.0
0.0
Retention time (min)
0.0 5.0 10.0
7
9
9 7
5
C
B
A
2
15.0 20.0
c1
25.0 35.0
0.0
20
40
60
A
b
s
o
r
b
a
n
c
e
 
a
t
 
3
4
0
 
n
m
80
100
9
9
9
Standards
ATRA
13cRA
9cRA
ROL
8
7
6
5
4 3
2
1
10
8
6 4 A
3
2 1
8
6 C
B
A
2
Figure 3 HPLC profiles of retinoid metabolites in the medium of 
UM-SCC-35 are shown after exposure to 10–6 mol–1 M of various retinoid
compounds for 24 h. The upper panel one is a HPLC profile of retinoid
standards dissolved in water. For identification of the peaks see the legend of
Figure 2 and in addition peak 10 corresponds to retinal. Peaks A, B and C
indicate unidentified compounds 634 I Klaassen et al 
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ATRA and 13cRA after 9cRA exposure (up to 5%) was found.
After exposure to ROL, a relatively high formation of ATRA in
UM-SCC-14C was seen and no or very small amounts of other
retinoids in UM-SCC-35 and UM-SCC-35R. 
DISCUSSION 
Treatment with 13cRA has shown several major drawbacks: it
exhibited considerable toxicity at therapeutic levels, was active in
only a proportion of the individuals with premalignant lesions and
when the treatment is stopped the lesions recur (Hong et al, 1986;
Hong et al, 1990). Other retinoic acid derivatives are being devel-
oped and tested, hoping that these derivatives may lack the nega-
tive effects of 13cRA and be able to provide similar or higher
efficacy, including activity against advanced cancer (Armstrong
and Meyskens, 2000). Recently, a randomized Phase I chemo-
prevention trial with ATRA in patients with curatively treated
HNSCC ended and a Phase II trial is on its way (Park et al, 2000). 
The present study showed that all retinoids tested were equally
active in HNSCC cell lines. Thus, although retinoids have different
binding affinities for the nuclear receptors (Allenby et al, 1993;
Sun et al, 1997), this apparently has no influence on the level of
growth inhibition in vitro. This finding suggests that all these
compounds induce growth inhibition through a common mecha-
nism. Evidence has been provided that retinoids regulate cellular
growth and differentiation through binding to retinoic acid recep-
tors (RARs) and retinoid X receptors (RXRs) (Mangelsdorf et al,
1994; Heyman et al, 1992). In particular, in HNSCC the binding to
RAR-γ has been suggested to be important for retinoid induced
growth inhibition. (Le et al, 2000; Klaassen et al, 2001b). So the
most likely explanation is that all retinoids are able, in a direct or
indirect way, to reach the downstream target, the retinoid receptor.
It remains to be explained why 13cRA is active in some HNSCC
lines whereas the binding affinity of 13cRA to both retinoic acid
receptor classes is negligible. It is very plausible that 13cRA is
converted to retinoids that have high enough levels to modulate
growth through binding to the retinoid receptors. 13cRA is
converted to its isomers ATRA and 9cRA and its breakdown
product 4-oxo-13cRA; all these compounds have receptor binding
property and a growth inhibiting activity (Figure 1). 
The retinoids used in this study were not able to improve the
sensitivity profile of the standard compound 13cRA. In the insen-
sitive cell lines ATRA, 9cRA and ROL did not enhance the level of
growth inhibition. It is possible that in these cell lines the receptor
system is seriously disrupted and that it will be very hard to find a
retinoid that will be active. 
We tested turnover rates of 13cRA, ATRA, 9cRA and ROL to
investigate whether these would explain differences in growth
inhibition between HNSCC cell lines. In the individual cell lines,
turnover rates of the three stereoisomers were in a narrow range,
and that of ROL somewhat higher. The most likely explanation for
the relatively higher turnover rate of ROL as compared to the other
retinoids might be that ROL can be converted to at least four
different compounds. Besides oxidation to ATRA via retinal, ROL
can also be esterified to retinyl-esters (Kurlandsky et al, 1996), 4-
hydroxylated to 4-oxo-ROL (Leo and Lieber, 1985), or metabo-
lized to anhydroretinol (Bhat et al, 1979). Esterification has been
studied in more detail by Guo and Gudas (1998). These authors
showed that HNSCC cells have a reduced capacity to esterify ROL
as compared to normal oral keratinocytes. This would explain the
relatively low turnover rate of ROL as compared to tumour cell
cultures, but whether this leads to differences in metabolites,
remains to be established. 
We also performed metabolic studies on normal OKC. These
cells were slow with respect to the rate of retinoid turnover and
were not able to synthesize polar metabolites. This confirms the
results of a previous study with ATRA (Klaassen et al, 2001a). 
The comparison of the retinoids with respect to metabolism
showed two phenomena that need further discussion. There was
only a small difference between the compounds in turnover rate
and each compound had its unique pattern of metabolites. With
respect to the rate of turnover it is known that the CYP-related
enzyme system is involved in the conversion (4-hydroxylation) to
polar retinoids, like 4-OH-RA, 18-OH-RA and 4-oxo-RA. For
instance, CYP26 was found to be responsible for the 4-hydroxyla-
tion of ATRA (Ray et al, 1997; White et al, 1997). CYP26 is
highly substrate (ATRA) specific and can not metabolize 13cRA
or 9cRA (Sonneveld et al, 1998). In the present study it was found
that 13cRA and 9cRA were catabolized with similar turnover rates
as ATRA, which suggests that one or more enzymes analogous to
CYP26 are responsible for the catabolism of 13cRA and 9cRA. To
a small degree, isomerization to ATRA can be involved, however
the finding that each retinoid has its unique pattern of metabolites
limits this possibility. Furthermore, other studies have shown
evidence that 4-hydroxylated forms of 9cRA and 13cRA are
directly formed from their parental compounds (Eckhoff and Nau,
1990; Dzerk et al, 1998). This strongly suggests that specific CYPs
exist that are responsible for the conversion of 9cRA and 13cRA
to their corresponding 4-oxo-compounds. The CYP isoform that
metabolizes cis- and trans-RA-isomers can be different as shown
with isomers of retinal. Raner et al (1996) demonstrated that in
vitro 4-hydroxylation of 13-cis- and all-trans-retinal was predomi-
nantly catalysed by the CYP1A1 isoform, whereas CYP2B4 and
CYP2C3 are most active in the metabolism of 9-cis-retinal. 
In conclusion, despite variation in their binding to retinoid
receptors, all retinoids did not differ with respect to their capacity
to induce growth inhibition. The rate at which the cells were able
to catabolize the retinoid was similar for all compounds. Cellular
metabolism in HNSCC cells leads to a metabolite profile that is
unique for each retinoid. 
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